Precision Lifesciences Group believes that the company’s proprietary cancer immunotherapy technology platform is broadly enabling, with the potential to generate many immunotherapeutic products that can improve cancer treatment and bring meaningful benefit to patients and their families.

 Use the “subscribe” box below to keep up to date on the latest news and developments.